TELCON RF PHARMACEUTICAL. Inc. (KOSDAQ:200230)
3,125.00
+55.00 (1.79%)
Apr 1, 2025, 3:30 PM KST
TELCON RF PHARMACEUTICAL. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 37,865 | 36,307 | 27,830 | 37,841 | 33,141 | Upgrade
|
Other Revenue | - | -0 | - | -0 | - | Upgrade
|
Revenue | 37,865 | 36,307 | 27,830 | 37,841 | 33,141 | Upgrade
|
Revenue Growth (YoY) | 4.29% | 30.46% | -26.46% | 14.18% | -41.44% | Upgrade
|
Cost of Revenue | 27,628 | 26,800 | 22,267 | 28,780 | 25,905 | Upgrade
|
Gross Profit | 10,237 | 9,507 | 5,563 | 9,061 | 7,236 | Upgrade
|
Selling, General & Admin | 6,252 | 4,484 | 4,554 | 6,949 | 7,391 | Upgrade
|
Research & Development | 722.94 | 733.17 | 1,208 | 1,635 | 1,817 | Upgrade
|
Other Operating Expenses | 112.54 | 59.76 | 68.03 | 168.3 | 53.62 | Upgrade
|
Operating Expenses | 10,307 | 8,542 | 9,626 | 13,624 | 9,326 | Upgrade
|
Operating Income | -70.55 | 965.32 | -4,063 | -4,563 | -2,090 | Upgrade
|
Interest Expense | -3,760 | -603.58 | -1,063 | -7,702 | -2,849 | Upgrade
|
Interest & Investment Income | 324.97 | 205.05 | 61.42 | 45.48 | 57.21 | Upgrade
|
Earnings From Equity Investments | -24,684 | 469.53 | -17,868 | -13,196 | -39,204 | Upgrade
|
Currency Exchange Gain (Loss) | 602.71 | 119.08 | 318.02 | 831.71 | 178.36 | Upgrade
|
Other Non Operating Income (Expenses) | 1,119 | -837.92 | -1,981 | 77.32 | -135.85 | Upgrade
|
EBT Excluding Unusual Items | -26,468 | 317.48 | -24,595 | -24,507 | -44,042 | Upgrade
|
Impairment of Goodwill | - | - | - | - | -4,179 | Upgrade
|
Gain (Loss) on Sale of Investments | 1,275 | 13,466 | -13,146 | 4,626 | 9,010 | Upgrade
|
Gain (Loss) on Sale of Assets | 17.27 | -14.8 | 34.38 | 10.31 | -179.33 | Upgrade
|
Asset Writedown | -1,097 | -64.8 | -4,411 | -3,005 | -51.13 | Upgrade
|
Other Unusual Items | -227.31 | 244.63 | - | - | -2,209 | Upgrade
|
Pretax Income | -26,500 | 13,949 | -42,117 | -22,875 | -41,652 | Upgrade
|
Income Tax Expense | - | - | - | - | 18.95 | Upgrade
|
Earnings From Continuing Operations | -26,500 | 13,949 | -42,117 | -22,875 | -41,671 | Upgrade
|
Earnings From Discontinued Operations | - | - | - | -331.42 | -355.73 | Upgrade
|
Net Income to Company | -26,500 | 13,949 | -42,117 | -23,207 | -42,027 | Upgrade
|
Minority Interest in Earnings | 180.11 | -42.34 | 32.81 | 108.8 | 1,134 | Upgrade
|
Net Income | -26,320 | 13,906 | -42,084 | -23,098 | -40,893 | Upgrade
|
Net Income to Common | -26,320 | 13,906 | -42,084 | -23,098 | -40,893 | Upgrade
|
Shares Outstanding (Basic) | 12 | 11 | 11 | 9 | 9 | Upgrade
|
Shares Outstanding (Diluted) | 12 | 15 | 14 | 9 | 9 | Upgrade
|
Shares Change (YoY) | -20.89% | 8.89% | 56.33% | 2.65% | 3.29% | Upgrade
|
EPS (Basic) | -2224.63 | 1243.94 | -3967.18 | -2629.30 | -4778.04 | Upgrade
|
EPS (Diluted) | -2225.00 | 1025.12 | -3967.18 | -2629.30 | -4781.56 | Upgrade
|
Free Cash Flow | -3,749 | -4,954 | -2,912 | -2,613 | 1,671 | Upgrade
|
Free Cash Flow Per Share | -316.87 | -331.29 | -212.06 | -297.40 | 195.25 | Upgrade
|
Gross Margin | 27.03% | 26.19% | 19.99% | 23.95% | 21.83% | Upgrade
|
Operating Margin | -0.19% | 2.66% | -14.60% | -12.06% | -6.31% | Upgrade
|
Profit Margin | -69.51% | 38.30% | -151.22% | -61.04% | -123.39% | Upgrade
|
Free Cash Flow Margin | -9.90% | -13.64% | -10.46% | -6.90% | 5.04% | Upgrade
|
EBITDA | 4,436 | 5,210 | 218.47 | -363.07 | 2,307 | Upgrade
|
EBITDA Margin | 11.72% | 14.35% | 0.78% | -0.96% | 6.96% | Upgrade
|
D&A For EBITDA | 4,507 | 4,244 | 4,281 | 4,200 | 4,397 | Upgrade
|
EBIT | -70.55 | 965.32 | -4,063 | -4,563 | -2,090 | Upgrade
|
EBIT Margin | -0.19% | 2.66% | -14.60% | -12.06% | -6.31% | Upgrade
|
Advertising Expenses | 35.06 | 10.77 | 45.18 | 3.36 | 18.62 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.